Renal Hemodynamics in Patients With HFpEF

• ClinicalTrials.gov Identifier: NCT03672591
• Recruitment Status: Completed
• First Posted: September 14, 2018
• Last Update Posted: July 10, 2019
• Sponsor: University of Erlangen-Nürnberg Medical School
• Information provided by (Responsible Party): Roland E. Schmieder, University of Erlangen-Nürnberg Medical School

Study Description

Brief Summary:

Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality. The relationship between HFpEF and renal impairment is bidirectional. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.

In the literature, several studies aimed to investigate the association between renal (dys-) function and HFpEF. In all these studies, renal function was assessed by determination of standard kidney function parameters such as serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). Constant infusion input clearance technique however offers a more detailed evaluation of renal function and hemodynamics. To the best of knowledge, renal hemodynamics in patients with HFpEF have not yet been investigated by clearance technique. Therefore, the aim of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with sodium p-aminohippuric acid (PAH) and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers an exact evaluation of renal function by measuring (not estimating) glomerular filtration rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects without HFpEF that have participated in various studies and have been analyzed with the same constant infusion input clearance technique performed in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. Additionally, flow mediated vasodilation (FMD), pulse wave velocity and parameters of retinal vascular remodeling by means of scanning laser Doppler flowmetry (SLDF) will be assessed in patients with HFpEF thereby allowing to examine the relationship between vascular remodeling in the systemic and renal circulation.

Condition or disease	Intervention/treatment
Heart Failure With Normal Ejection Fraction	Other: Renal clearance examination

Detailed Description:

Several studies evaluating the outcome among patients with HFpEF revealed that this entity of heart failure (HF) is associated with high mortality rates and some studies even indicate that mortality is similar to patients with heart failure and reduced ejection fraction (HFrEF). Hospitalization for HFpEF is increasing relative to HFrEF, highlighting the need for a better understanding of the pathogenetic processes in order to develop new treatment strategies for this type of HF. Recently, the PARAMOUNT study revealed that in patients with HFpEF, treatment with the dual-acting angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 was associated with lower levels of creatinine and higher estimated glomerular filtration rates (eGFR) indicating a better preservation of renal function in comparison to treatment with valsartan only. Another observation of this study was an increase in urinary albumin to creatinine ratio (UACR) in the group of LCZ696-treatment, which was not visible in patients randomized to the valsartan group. Additionally, analysis of the relation between albuminuria and/or decreased eGFR and cardiovascular function and structure revealed that renal dysfunction was common in this group of patients and associated with cardiac remodeling and dysfunction.

Up to two thirds of patients with HFpEF are suffering from chronic kidney disease (CKD). A bidirectional cardiorenal relation has been recently described and is known to be associated with adverse cardiovascular outcome and increased mortality. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF due to inflammatory processes and endothelial dysfunction. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described.

This association has also been demonstrated for patients with HFrEF. However, several studies comparing patients with the two subtypes of HF in the context of CKD indicate that this association is more pronounced in patients with HFpEF. For example, a community-based cohort study by Brouwers et al. including 8592 subjects of the PREVEND trial showed that renal function parameters such as urinary albumin excretion (UAE) and cystatin C were associated with a high risk for the development of HFpEF but not HFrEF. Ahmed et al. even reported a higher CKD-related mortality in HFpEF than in HFrEF patients with an underlying graded-response relation as CKD-associated mortality increased with higher left ventricular ejection fraction (LVEF). These findings suggest different pathogenetic processes for these two subtypes of HF. Therefore, detailed exploration of the pathophysiological mechanisms behind the relationship of HFpEF and renal function represents a matter of major research interest.

Recently, several studies aimed to investigate the association between renal (dys-) function and HFpEF. Unger et al. retrospectively examined the relationship between renal function and echocardiographic parameters in 299 patients with HFpEF. The analysis revealed that CKD was independently associated with worse cardiac mechanics and outcomes in this population.9 Studying 217 participants from the PARAMOUNT trial with HFpEF, Gori et al. demonstrated that renal dysfunction was associated with abnormal left ventricular geometry, lower midwall fractional shortening and higher NT-proBNP. In both studies, renal function was assessed with commonly used tests such as determination of serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). However, these parameters only allow an approximate estimation of renal function. Constant infusion input clearance technique offers a more complete approach towards evaluation of renal function and perfusion, allowing an exact quantification of glomerular filtration rate (GFR) and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular hemodynamics.

The definition of HFpEF in literature is rather inconsistent. In some studies, HFpEF was defined by an ejection fraction of ≥ 45%, whereas other authors used a cut-off value of 50%. In the present study, the categorization of heart failure as HFpEF will follow the 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure applying a cut-off value of 50%.

The purpose of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with PAH and Iohexol in 40 patients with HFpEF with the aim to better characterize the relationship between renal dysfunction and HFpEF. These results will be compared to 140 subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. In parallel, pulse wave velocity, flow mediated vasodilation and other vascular parameters, reflecting the vascular wall properties of small and large arteries, will be assessed. Additionally, there will be a non-invasive retinal examination to assess vascular remodeling of retinal arterioles (wall to lumen ratio, WLR), retinal capillary flow (RCF) and capillary rarefaction.

Study Design

• Study Type: Observational
• Actual Enrollment: 40 participants
• Observational Model: Case-Control
• Time Perspective: Cross-Sectional
• Official Title: Cross-sectional Observational Single-center Study to Evaluate Renal Hemodynamics in Patients With Heart Failure and Preserved Ejection Fraction
• Actual Study Start Date: November 30, 2018
• Actual Primary Completion Date: June 30, 2019
• Actual Study Completion Date: June 30, 2019

Groups and Cohorts

Group/Cohort	Intervention/treatment
HFpEF patients; Patients suffering from heart failure with preserved ejection fraction	Other: Renal clearance examination; Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol; Other Name: Scanning laser Doppler flowmetry, SphygmoCor, UnexEF
Control group; Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)	Other: Renal clearance examination; Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol; Other Name: Scanning laser Doppler flowmetry, SphygmoCor, UnexEF

Outcome Measures

Primary Outcome Measures :

1. Renal plasma flow [ Time Frame: One week after study inclusion ]
   Volume of blood plasma delivered to the kidneys per unit time (ml/min)

Secondary Outcome Measures :

1. Flow mediated vasodilation [ Time Frame: One week after study inclusion ]
   Measured by UNEX EF in percent
2. Wall to lumen ratio of retinal arterioles [ Time Frame: One week after study inclusion ]
   ratio of vascular wall thickness to luminal diameter
3. Retinal capillary flow [ Time Frame: One week after study inclusion ]
   by SLDF measurement in AU
4. Office and 24-hour systolic, diastolic and mean ambulatory blood pressure [ Time Frame: One week after study inclusion ]
   in mmHg
5. Central systolic pressure [ Time Frame: One week after study inclusion ]
   measured by SphygmoCor in mmHg
6. Pulse pressure [ Time Frame: One week after study inclusion ]
   difference between systolic and diastolic blood pressure in mmHg
7. Pulse wave velocity [ Time Frame: One week after study inclusion ]
   velocity at which the blood pressure pulse propagates through the circulatory System measured by SphygmoCor in m/s
8. Glomerular filtration rate [ Time Frame: One week after study inclusion ]
   Flow rate of filtered fluid through the kidney in ml/min/1.73m^2
9. Filtration fraction [ Time Frame: One week after study inclusion ]
   Ratio of glomerular filtration rate to renal plasma flow in percent
10. Renal vascular resistance [ Time Frame: One week after study inclusion ]
    Calculated by the Gomez formula in dyn x sec x cm^-5
11. Intraglomerular pressure [ Time Frame: One week after study inclusion ]
    in mmHg

Biospecimen Retention:   Samples Without DNA

• Biochemistry (urea, serum creatinine, eGFR, cystatin C, uric acid, sodium, potassium, calcium, phosphate, lipid levels, total protein, SGOT, SGPT, AP, ɣ-GT)
• Hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count)
• Fasting blood glucose, HbA1c
• NT-proBNP
• TSH
• Spot-urine (urinary creatinine and albumin, urinary sodium and potassium)
• Urinary dip stick analysis

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 85 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Probability Sample

Study Population

HFpEF patients: recruitment from the investigator's outpatient clinics and referring physicians.

Control subjects without HFpEF: individuals who already participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)

Criteria

Inclusion Criteria:

• Patients in good and stable health condition
• Informed consent has to be given in written form

• HFpEF in stable conditions according to 2016 ESC guidelines definition14

  • LVEF ≥ 50%
  • symptoms and/or signs of CHF
  • NT-proBNP > 125 pg/ml
  • At least one additional criterion: relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement and/or diastolic dysfunction

Exclusion Criteria:

• Uncontrolled diabetes (fasting plasma glucose ≥ 240 mg/dl, HbA1c ≥ 10%)
• Uncontrolled arterial hypertension (≥ 180/110 mmHg)
• Any history of stroke, transient ischemic attack, instable angina pectoris or myocardial infarction within the last 6 months prior to study inclusion
• Significant valvular heart disease
• Known hypertrophic obstructive cardiomyopathy or known pericardial constriction
• Atrial fibrillation with a resting heart rate > 90 bpm
• Heart transplant recipient
• Sickle cell anemia
• Pheochromocytoma
• Myasthenia gravis
• Subclinical or clinical hyperthyroidism
• Allergic reaction to iodine
• Medication with amiodarone
• Estimated glomerular filtration rate < 30 ml/min/1.73m²
• Significant laboratory abnormalities such as Serum Glutamate-Oxaloacetate-Transaminase (SGOT) or Serum Glutamate-Pyruvate-Transaminase (SGPT) levels more than 3 times above the upper limit of normal range
• Patients in unstable conditions due to any kind of serious disease, that infers with the conduction of the trial
• History of epilepsia and history of seizures
• Patients suffering from cataract or glaucoma
• Diabetic retinopathy
• Drug or alcohol abuse
• Pregnant and breast-feeding patients
• Body mass index > 40 kg/m²
• Participation in another clinical study within 30 days prior to visit 1
• Individuals at risk for poor protocol adherence
• Subjects who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V

Contacts and Locations

Locations

Germany

Clinical Research Center Erlangen, Department of Nephrology and Hypertension, University Hospital Erlangen

Erlangen, Germany

Clinical Research Center Nuremberg, Department of Nephrology, University Hospital Erlangen

Nuremberg, Germany

Sponsors and Collaborators

University of Erlangen-Nürnberg Medical School

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jung S, Bosch A, Kolwelter J, Striepe K, Kannenkeril D, Schuster T, Ott C, Achenbach S, Schmieder RE. Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2021 Apr;8(2):1562-1570. doi: 10.1002/ehf2.13257. Epub 2021 Feb 9.

• Responsible Party: Roland E. Schmieder, Head of the Clinical Research Center, University of Erlangen-Nürnberg Medical School
• ClinicalTrials.gov Identifier: NCT03672591
• Other Study ID Numbers: CRC2018HFpEF
• First Posted: September 14, 2018
• Last Update Posted: July 10, 2019
• Last Verified: July 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Roland E. Schmieder, University of Erlangen-Nürnberg Medical School:

Heart failure; Renal clearance technique; Preserved ejection fraction

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases